NVO
Price
$106.40
Change
-$0.51 (-0.48%)
Updated
Nov 14, 11:56 AM (EDT)
83 days until earnings call
SCPX
Price
$0.74
Change
-$0.06 (-7.50%)
Updated
Nov 13 closing price
Ad is loading...

NVO vs SCPX

Header iconNVO vs SCPX Comparison
Open Charts NVO vs SCPXBanner chart's image
Novo-Nordisk A/S
Price$106.40
Change-$0.51 (-0.48%)
Volume$4.5K
CapitalizationN/A
SCORPIUS HOLDINGS
Price$0.74
Change-$0.06 (-7.50%)
Volume$98.29K
CapitalizationN/A
NVO vs SCPX Comparison Chart
Loading...
NVO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
NVO vs. SCPX commentary
Nov 14, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVO is a Buy and SCPX is a Buy.

COMPARISON
Comparison
Nov 14, 2024
Stock price -- (NVO: $106.91 vs. SCPX: $0.74)
Brand notoriety: NVO and SCPX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVO: 63% vs. SCPX: 80%
Market capitalization -- NVO: $473.6B vs. SCPX: $2.31M
NVO [@Biotechnology] is valued at $473.6B. SCPX’s [@Biotechnology] market capitalization is $2.31M. The market cap for tickers in the [@Biotechnology] industry ranges from $473.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.76B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVO’s FA Score shows that 3 FA rating(s) are green whileSCPX’s FA Score has 1 green FA rating(s).

  • NVO’s FA Score: 3 green, 2 red.
  • SCPX’s FA Score: 1 green, 4 red.
According to our system of comparison, NVO is a better buy in the long-term than SCPX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVO’s TA Score shows that 4 TA indicator(s) are bullish.

  • NVO’s TA Score: 4 bullish, 4 bearish.

Price Growth

NVO (@Biotechnology) experienced а +1.47% price change this week, while SCPX (@Biotechnology) price change was -8.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.78%. For the same industry, the average monthly price growth was +4.53%, and the average quarterly price growth was +7.16%.

Reported Earning Dates

NVO is expected to report earnings on Feb 05, 2025.

SCPX is expected to report earnings on Nov 11, 2024.

Industries' Descriptions

@Biotechnology (-0.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVO($474B) has a higher market cap than SCPX($2.31M). NVO YTD gains are higher at: 4.483 vs. SCPX (-99.157). NVO has higher annual earnings (EBITDA): 134B vs. SCPX (-23.14M). NVO has higher revenues than SCPX: NVO (258B) vs SCPX (9.85M).
NVOSCPXNVO / SCPX
Capitalization474B2.31M20,501,730%
EBITDA134B-23.14M-579,101%
Gain YTD4.483-99.157-5%
P/E Ratio35.43N/A-
Revenue258B9.85M2,620,620%
Total CashN/A1.51M-
Total DebtN/A15.9M-
FUNDAMENTALS RATINGS
NVO vs SCPX: Fundamental Ratings
NVO
SCPX
OUTLOOK RATING
1..100
5678
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
7
Undervalued
PROFIT vs RISK RATING
1..100
14100
SMR RATING
1..100
1497
PRICE GROWTH RATING
1..100
6365
P/E GROWTH RATING
1..100
81100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVO's Valuation (2) in the Pharmaceuticals Major industry is in the same range as SCPX (7) in the Biotechnology industry. This means that NVO’s stock grew similarly to SCPX’s over the last 12 months.

NVO's Profit vs Risk Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for SCPX (100) in the Biotechnology industry. This means that NVO’s stock grew significantly faster than SCPX’s over the last 12 months.

NVO's SMR Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for SCPX (97) in the Biotechnology industry. This means that NVO’s stock grew significantly faster than SCPX’s over the last 12 months.

NVO's Price Growth Rating (63) in the Pharmaceuticals Major industry is in the same range as SCPX (65) in the Biotechnology industry. This means that NVO’s stock grew similarly to SCPX’s over the last 12 months.

NVO's P/E Growth Rating (81) in the Pharmaceuticals Major industry is in the same range as SCPX (100) in the Biotechnology industry. This means that NVO’s stock grew similarly to SCPX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVO
RSI
ODDS (%)
Bullish Trend 1 day ago
73%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
66%
Momentum
ODDS (%)
Bearish Trend 1 day ago
43%
MACD
ODDS (%)
Bearish Trend 1 day ago
57%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
67%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
50%
Advances
ODDS (%)
Bullish Trend 29 days ago
69%
Declines
ODDS (%)
Bearish Trend 1 day ago
47%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
75%
Aroon
ODDS (%)
Bearish Trend 1 day ago
46%
View a ticker or compare two or three
Ad is loading...
NVO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
CPNG25.901.39
+5.67%
Coupang
AAT27.35-0.07
-0.26%
American Assets Trust
GWRS12.68-0.14
-1.13%
Global Water Resources
LU2.41-0.03
-1.23%
Lufax Holding Ltd
LEXX2.25-0.05
-2.17%
Lexaria Bioscience Corp

SCPX and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCPX has been loosely correlated with SPRB. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if SCPX jumps, then SPRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCPX
1D Price
Change %
SCPX100%
-7.48%
SPRB - SCPX
43%
Loosely correlated
-2.78%
FENC - SCPX
39%
Loosely correlated
+6.15%
VRPX - SCPX
37%
Loosely correlated
N/A
ALVR - SCPX
34%
Loosely correlated
+4.04%
BOLT - SCPX
33%
Loosely correlated
-2.46%
More